期刊
EXPERT REVIEW OF HEMATOLOGY
卷 7, 期 4, 页码 439-464出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/17474086.2014.932687
关键词
acute myeloid leukemia; small molecule inhibitor; therapeutic agent
类别
资金
- National Institutes of Health/National Cancer Institute [NIH/NCI P01 CA101937, NIH/NCI R01 CA152329]
Many patients with acute myeloid leukemia will eventually develop refractory or relapsed disease. In the absence of standard therapy for this population, there is currently an urgent unmet need for novel therapeutic agents. Targeted therapy with small molecule inhibitors represents a new therapeutic intervention that has been successful for the treatment of multiple tumors (e. g., gastrointestinal stromal tumors, chronic myelogenous leukemia). Hence, there has been great interest in generating selective small molecule inhibitors targeting critical pathways of proliferation and survival in acute myeloid leukemia. This review highlights a selective group of intriguing therapeutic agents and their presumed targets in both preclinical models and in early human clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据